CEOs of Bavarian Nordic and Elusys Therapeutics elected as new co-chairs of Alliance for Biosecurity
Hedegaard and Posillico will each serve a two-year term as representatives of the Alliance before the U.S. government and other agencies in an effort to advance the development of new medical countermeasures against chemical, biological, radiological and nuclear threats.
"Alliance members applaud the recent five-year reauthorization of the Pandemic and All-Hazards Preparedness Act, which extends funding for Project BioShield and also enacts initiatives to speed the development of medical countermeasures," Hedegaard said. "We look forward to working with elected officials to safeguard public health by ensuring that important vaccines and therapeutics against life-threatening infectious diseases continue to be developed, supplied and are available when needed."
The alliance successfully advocated for the preservation of the Biomedical Advanced Research and Development Authority and the BioShield Special Reserve Fund to keep funding in place for the development and procurement of MCMs. Several recommendations by the alliance for improving the regulatory pathway for MCMs and more effectively integrating the U.S. Food and Drug Administration into the development process were adopted in recent legislation.
"We are at a critical time, where further funding, research and development of medical countermeasures are necessary to ensure that preparedness programs continue to be carefully planned and sustained over the long-term, creating the national capabilities needed to protect Americans from public health threats," Posillico said. "Our efforts at the alliance will also help to promote the success of BARDA and its important work developing medical countermeasures against a broad array of public health threats."
The Alliance for Biosecurity was formed in 2005 with the goal of improving U.S. biosecurity through developing MCMs to address natural pandemic and bioterrorism threats.